Aristotle University Of Thessaloniki (AUTH)
Φαρμακοκινητική και φαρμακοδυναμική μελέτη της μοξιφλοξασίνης στη λοιμώδη παρόξυνση της ΧΑΠ
Abstract
dc:descriptionCOPD is a worldwide disease that can be prevented and treated. It is the fourth leading cause of death worldwide and is projected to be the third by 2020. Patients with COPD are characterized by chronic morbidity and high mortality, that’s why is both a social issue and a public health challenge. Exacerbations have been found to worsen the clinical profil of the patient and accelerate the decline in respiratory function. The reduction of the incidence per year and adequate treatment is a primary goal for physicians. The choice of the appropriate antibiotic for exacerbation is of great importance as it relates to the restoration of respiratory function and the recurrence period after exacerbation. The efficacy of the drug to be administered is mainly determined by its pharmacokinetic properties and its penetration into the secretions of patients.In addition, in critically ill ICU patients, this choice is further complicated as the pathophysiological conditions fluctuate pharmacokinetics of the drugs. It is therefore important to know that the antibiotic administered achieves good serum concentrations and exudates of exacerbated patients whether treated in the ward or ICU. The purpose of this study was to evaluate the pharmacokinetic profile of moxifloxacin in plasma and secretions of COPD exacerbations, to determine its penetration in sputum and bronchial secretions, as well as to evaluate its pharmacodynamic against the main pathogens of mild and moderate COPD exacerbation.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Sionidou, Maria
- Σιωνίδου, Μαρία
Subjects
dc:subject × 8Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46821